Home / Digital Academy

Digital Academy

 

Drs. Laurence Mignon, Ph.D., director of clinical development at Ionis Pharmaceuticals, and Michael Horrigan, M.D., chief medical officer at AMO Pharma, present updates on the status of Phase I/II clinical trials current underway at their industry institutions for potential DM1 therapies – at the 2016 MDF Annual Conference.

 

Dr. Lauren Wood, director of neuromuscular research in the rare disease research unit at Pfizer, Inc., presents an overview of the progress achieved in DM1 drug development at Pfizer to date, and anticipated next steps for clinical trial development – at the 2016 MDF Annual Conference.

 

Drs. John Day, M.D., Ph.D, of Stanford University, Chad Heatwole, M.D., of the University of Rochester and Giovanni Meola, M.D., of the University of Milan present an overview of DM-related disease impacts and symptoms, and the current status of brain-related DM research – at the 2016 MDF Annual Conference.

 

MDF Chief Executive Officer Molly White provides a look back at the first 10 years of MDF programming and research progress, and the significant accomplishments achieved – at the 2016 MDF Annual Conference.

 

Dr. Cynthia Gagnon, Ph.D., a professor and member of the interdisciplinary research group on neuromuscular disorders at the University of Sherbrooke in Quebec, CA.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.